ArticleInfection2025
Predictors of mortality of enterococcal bacteraemia and the role of source control interventions; a retrospective cohort study.
Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A 5-Year Population-Based Study of Polymicrobial Enterococcal Bloodstream Infection in Southeast Minnesota.Mayo Clinic proceedings · 2026Article
- Outcomes of linezolid, glycopeptides, and other regimens in ampicillin-resistant, vancomycin-susceptible and vancomycin-resistant enterococcal bacteremia in a resource-limited setting: stewardship implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Antimicrobial Resistance and Clinical Outcomes of Uropathogenic Enterococcal Infections in Hospitalised Patients.Cureus · 2026Article
- Evaluation of the MEFIER Score in Identifying Patients at High Risk of Endocarditis inOpen forum infectious diseases · 2026Article
- Short course of antimicrobial treatment for uncomplicated enterococcal bacteremia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Impact of Vancomycin Resistance on 30-Day Mortality in Solid Organ Transplant Recipients withAntibiotics (Basel, Switzerland) · 2026Article
- Clinical Outcomes of Penicillin-Based Therapy Compared to Alternative Enterococcal Treatment in Patients With Vancomycin-Susceptible Enterococcal Bloodstream Infections: A Monocentric Cohort Study.Transboundary and emerging diseases · 2026Article
- Prediction Scores Identifying Patients at High Risk of Endocarditis in Enterococcal Bacteremia.Open forum infectious diseases · 2026Article
- Who is at risk? Clinical features and a predictive model for 30-day mortality in hematologic patients with enterococcal bloodstream infection.Frontiers in cellular and infection microbiology · 2026Article
- Evaluating Blood Culture Parameters to Identify Patients at Low Risk of Infective Endocarditis Among Those With Bacteremia by Gram-positive Cocci.Open forum infectious diseases · 2025Article
- Evaluation of Different Versions of the Duke Criteria for the Diagnosis of Infective Endocarditis Among Patients With Enterococcal Bacteremia; a Multicenter Study.Open forum infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify predictors of mortality among patients with enterococcal bacteraemia.
methodsThis retrospective study was conducted at the Lausanne University Hospital, Switzerland and included adult patients with enterococcal bacteraemia from 2014 to 2023.
resultsDuring the study period, 768 enterococcal bacteraemia episodes were included. The predominant species was Enterococcus faecalis (427 episodes; 56%). Sepsis or septic shock were present in 351 (46%) episodes. The overall 30-day mortality rate was 19% (148 episodes). The Cox multivariable regression model showed that age > 60 years (aHR: 1.75, 95% CI: 1.05-2.90), nosocomial infection (1.78, 1.19-2.65), sepsis or septic shock (3.67, 2.48-5.45), and not performing source control interventions within 48 h, in patients on or discussing of transitioning to limitations of care (5.91, 3.13-11.14) were associated with 30-day mortality. Conversely, infectious diseases (ID) consultation within 48 h (0.40, 0.28-0.57), appropriate antimicrobial therapy within 48 h (0.54, 0.34-0.86), and source control interventions performed within 48 h (0.22, 0.14-0.36) or not warranted (0.54; 0.34-0.86) were associated with survival. Among the 737 episodes without limitation of care, the Cox multivariable regression model showed that nosocomial infection (1.78, 1.19-2.67), sepsis or septic shock (3.76, 2.42-5.82), were associated with 30-day mortality. Conversely, ID consultation within 48 h (0.44, 0.30-0.65), appropriate antimicrobial therapy within 48 h (0.51, 0.30-0.86), and source control interventions performed within 48 h (0.25, 0.16-0.40) or not warranted (0.40; 0.26-0.61) were associated with survival.
conclusionsOur findings underscore the pivotal role of early management of enterococcal bacteraemia, including ID consultation, appropriate antimicrobial treatment initiation and performance of source control interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.